When Joe Biden, President of the United States, and Dr. Anthony Fauci, Director of the National Institue of Allergy and Infectious Diseases, developed a COVID rebound despite taking Pfizer’s Paxlovid medication, it raised national concern over whether this antiviral treatment had long-run detrimental effects on the immune system.
Paxlovid was considered ground-breaking for COVID treatment when it was initially approved by the Food and Drug Administration (FDA). The 5-day antiviral course had patients feeling better in no time but as the drug became readily available to the masses, a Paxlovid rebound problem occurred. Although the medication had people recover quicker than otherwise, it was observed that once the course was over, COVID symptoms continued to prevail 2 to 8 days after recovery. Another characteristic of the Paxlovid rebound that the Centre for Disease Control and Prevention (CDC) describes is a positive COVID-19 test followed a week or so after the initial negative result.
An intensive investigation at the Clinical Centre of the National Institute of Health was conducted by U.S. researchers. 8 rebound patients were taken for the study the results of which were published in the journal Clinical Infectious Diseases to clear out any concerns that rose regarding the situation. The study found that patients who experienced a rebound had higher levels of antibodies compared to other patients.
The team conducting the study has reported, “The resurgence of COVID symptoms cannot be attributed to a weaker immune system, it in fact proves the opposite. These symptoms manifest due to the presence of a robust immune system.”
The study contained reports from individuals who adhered to the five-day prescribed course of Paxlovid and saw a return in symptoms once it was over. Another constant among all study participants was that they had all been vaccinated and boosted and were also infected with the same version of the virus. From the study, 6 people were those whose COVID symptoms returned after taking Paxlovid, and two who previously thought they had recovered without the help of pills but later exhibited rebound symptoms. The responses from these 6 participants were compared against another 6 participants who had suffered from COVID but did not rebound.
At the end of the study, it was concluded that all rebound patients showed significant improvement in their symptoms before the rebound and the majority of the volunteers in the study who had rebounded after taking the Paxlovid medication showed milder symptoms than those they experienced during the initial infection.
It was also determined that taking any additional doses over the recommended 5-day course would not yield any additional benefit in reducing the risk of the symptoms reoccurring.
However, there is still a need for larger and more in detailed studies to properly understand the rebound phenomenon. While the current data suggests isolating patients who experience the rebound just as you would with any patient that first comes in with COVID, it is also important to study the effects of the drug on individuals with a compromised immune system. Although it is more common to experience a COVID rebound after taking Paxlovid, there is also a possibility for this to happen even if you don’t take any medication.
